Market Overview

Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)

Share:

Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)

PR Newswire

LONDON, August 9, 2018 /PRNewswire/ -- Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs.

Download the full report: https://www.reportbuyer.com/product/5483274

Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension. PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.

Pulmonary arterial hypertension is a severe condition and there is no cure to PAH at present time. Many treatments are available to improve symptoms, quality of life and to keep the condition under control. There are currently four classes of drugs approved for the treatment of PAH and 13 approved products are available for PAH in the market across these four drug classes.

The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH.
The global PAH market is expected to grow in the future due to increasing ageing population, rise in healthcare expenditure, growing women population, increase in obese population and high unmet needs. Key trends of this market include increasing number of cardiovascular diseases, rising government support, and consumption of junk food. However, there are some factors which can hinder the growth of the market which includes patent expiration, high cost and lack of awareness.

The report "Global Pulmonary Arterial Hypertension Market: Industry Analysis & Outlook (2018-2022)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States and Europe region along with the global market. The report profiles the key players in the market including Johnson & Johnson, Gilead Sciences, United Therapeutics and GlaxoSmithKline.

Download the full report: https://www.reportbuyer.com/product/5483274

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/global-pulmonary-arterial-hypertension-pah-market-industry-analysis--outlook-2018-2022-300694879.html

SOURCE ReportBuyer

View Comments and Join the Discussion!